Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, has announced that its portfolio company BioreclamationIVT has completed the acquisition of West Sussex, UK-based SeraLabs. The company is a distributor of biological products to the early-stage drug discovery and development industry. Terms of the transaction were not disclosed.
BioreclamationIVT’s ongoing mission is to provide researchers with a one-stop shop for the biological tools necessary for the pursuit of new drug discovery and development, and to validate the safety and efficacy of new compounds during pre-clinical research and in clinical diagnostics.
According to TSCP Managing Director Bob Dunn, Thompson Street’s BioreclamationIVT has greatly expanded its European distribution capabilities with the acquisition of this UK-based distributor of biological products. “SeraLabs is an exciting addition to our rapidly growing platform. With this acquisition, we’ve increased our capabilities to serve researchers operating throughout Europe,” commented Mr. Dunn. “We’re looking forward to supporting the company’s continued expansion – both organically and via additional complementary acquisitions.”